0841 GMT - Uncertainty remains across the pharmaceutical industry until there is better visibility around the potential impact of U.S. tariffs, Shore Capital analyst Sean Conroy says in a note. U.S. President Trump announced across-the-board 10% tariffs on Wednesday on all imports and a 20% tariff on EU goods which, for now, exempts pharmaceuticals. GSK confirmed that there would be no changes to its outlook, whereas AstraZeneca said it will assess the implications of Trump's tariff announcement and Roche said it would consider additional U.S. investments. Shore Capital anticipates that stock prices might remain weak until companies can quantify the potential impact of tariffs on earnings and revenue, Conroy says. GSK's shares are up 1.5%, while AstraZeneca's are up 1.6% and Roche's are down 2.1%. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 03, 2025 04:41 ET (08:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。